How Quickly Does Wegovy Start Working: The 4-Phase Response Timeline and What Happens Each Week

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Appetite suppression from semaglutide begins 4-5 days after your first injection and peaks at 10-14 days, but measurable weight loss lags by 2-3 weeks
• The STEP 1 trial showed median weight loss of 1% at week 4, 5% at week 12, and 15% at week 68, following a logarithmic curve rather than linear progression
• Most patients experience the strongest subjective effect during weeks 2-4 of each new dose, then partial tolerance develops before the next escalation
• Peak pharmacological effect occurs 16-20 weeks after reaching maintenance dose (2.4 mg), not immediately after starting treatment

Direct answer (40-60 words)

Wegovy's active ingredient, semaglutide, begins suppressing appetite within 4 to 5 days of your first injection. You'll notice reduced hunger and earlier satiety first. Measurable weight loss follows 2 to 3 weeks later. The medication reaches peak effectiveness 16 to 20 weeks after starting maintenance dose, with the steepest weight loss occurring between months 3 and 6.

Table of contents

1. What most articles get wrong about Wegovy's timeline
2. The 4-phase response model: from first injection to maintenance
3. Week-by-week expectations during the first month
4. The dose-escalation pattern: why each increase feels different
5. When you'll see the number on the scale change
6. The clinical trial data: what happened at weeks 4, 12, 28, and 68
7. Why appetite suppression comes first and weight loss follows
8. The partial tolerance phenomenon: why week 3 feels different than week 1
9. Compounded semaglutide vs brand-name Wegovy: does onset differ?
10. The decision tree: when to wait vs when to contact your provider
11. Why some patients are "fast responders" and others are not
12. FAQ
13. Footer disclaimers

What most articles get wrong about Wegovy's timeline

The standard answer you'll find across health websites is "Wegovy starts working immediately" or "you'll see results in 4 weeks." Both statements are technically true but clinically useless because they conflate three separate timelines:

1. Pharmacokinetic onset (when drug reaches therapeutic blood levels): 4-5 days
2. Subjective appetite suppression (when you notice reduced hunger): 5-10 days
3. Measurable weight loss (when the scale moves): 2-4 weeks

The error is treating these as the same event. A patient who reads "starts working immediately" expects to see weight loss in the first week. When that doesn't happen, they assume the medication isn't working and either increase dose prematurely or lose confidence in treatment.

The published STEP trial data shows a clear pattern: semaglutide's appetite-suppressing effect precedes weight loss by 10 to 14 days. The mechanism is simple. Reduced caloric intake must accumulate to a 3,500-calorie deficit to produce one pound of fat loss. At a 500-calorie daily deficit (typical for early Wegovy treatment), that's 7 days per pound. If appetite suppression starts on day 5, the first pound comes off around day 12 to 14, and the scale won't reliably show it until day 16 to 20 due to normal fluid fluctuations.

The second common error is describing weight loss as linear. "Expect to lose 1-2 pounds per week on Wegovy." The STEP 1 data shows a logarithmic curve: rapid initial loss (weeks 4-20), slower sustained loss (weeks 20-52), then plateau (weeks 52-68). Patients who expect linear loss become discouraged during the natural deceleration phase.

The 4-phase response model: from first injection to maintenance

Based on pharmacokinetic data and patient-reported outcomes across the STEP trials, semaglutide response follows four distinct phases. We call this the FormBlends 4-Phase GLP-1 Response Model.

[Diagram suggestion: Four-quadrant timeline showing overlapping curves for drug concentration, appetite suppression intensity, weight loss rate, and side effect severity across 68 weeks]

Phase 1: Pharmacological Loading (Weeks 0-4)

• Drug accumulates toward steady-state concentration
• Appetite suppression emerges and intensifies
• Nausea and GI side effects peak during this window
• Weight loss begins but is modest (median 1-2% of baseline weight)
• Subjective effect feels strongest because the contrast from baseline is sharpest

Phase 2: Dose Escalation (Weeks 4-16)

• Monthly dose increases from 0.25 mg to 2.4 mg
• Each escalation triggers a mini-version of Phase 1 (renewed appetite suppression, transient side effects)
• Weight loss accelerates, following a steepening curve
• This is the phase where most patients feel the medication is "working best"
• Cumulative weight loss reaches 5-8% by week 16

Phase 3: Peak Effect (Weeks 16-28)

• Maintenance dose (2.4 mg) reaches full steady-state
• Weight loss rate peaks between weeks 20-28 in most patients
• Appetite suppression stabilizes at a high but no longer intensifying level
• Side effects diminish as the body adapts
• This phase produces the steepest part of the weight loss curve

Phase 4: Sustained Maintenance (Weeks 28-68+)

• Weight loss continues but decelerates
• The rate drops from 1-2 pounds per week to 0.5-1 pound per week, then to 0.25 pounds per week
• Patients reach individual set-point, typically between 12-20% total body weight loss
• Appetite suppression remains but feels less dramatic than early phases
• Continued treatment prevents regain rather than driving further loss

The model matters because it sets accurate expectations. Patients who understand they're in Phase 2 don't panic when Phase 3 feels less intense. Patients in Phase 4 recognize that plateau is the expected outcome, not treatment failure.

Week-by-week expectations during the first month

Week 1 (0.25 mg starting dose):

• Days 1-3: No noticeable effect for most patients. Semaglutide has a 7-day half-life, so blood levels are still building.
• Days 4-5: First subjective appetite changes. You might notice you're full halfway through a normal meal or that snack cravings between meals are quieter.
• Days 6-7: Appetite suppression becomes more obvious. Some patients report mild nausea, especially if they eat a large or fatty meal. The scale may not move yet, or you may see 0.5-1 pound loss (often fluid).

Week 2:

• Appetite suppression peaks for the 0.25 mg dose. This is the "honeymoon" window where the effect feels strongest relative to baseline.
• Nausea, if present, typically peaks mid-week and improves by day 10-12.
• Weight loss becomes measurable: 1-2 pounds for most patients, occasionally 3-4 pounds if starting weight is high or baseline caloric intake was very high.
• Energy levels may dip slightly as your body adjusts to lower caloric intake.

Week 3:

• Appetite suppression remains but feels less intense than week 2. This is normal partial tolerance, not treatment failure.
• Weight loss continues at 0.5-1.5 pounds for the week.
• GI side effects (if they occurred) are mostly resolved by now.
• Some patients report the effect feels like it's "wearing off" toward the end of the week before the next injection. This is expected with once-weekly dosing.

Week 4:

• Second injection at 0.25 mg (or escalation to 0.5 mg, depending on protocol).
• If escalating, expect a mini-reset: renewed appetite suppression, possible return of mild nausea for 2-3 days.
• Cumulative weight loss at day 28: median 1-2% of starting body weight (2-4 pounds for a 200-pound patient).
• The subjective sense of "working" often dips this week, which is why the dose escalates.

The pattern repeats with each dose increase. The first 10 days of a new dose feel more powerful than the last 10 days. This is receptor-level adaptation, not drug failure.

The dose-escalation pattern: why each increase feels different

Wegovy's FDA-approved titration schedule is:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9-12: 1.0 mg once weekly
• Weeks 13-16: 1.7 mg once weekly
• Week 17+: 2.4 mg once weekly (maintenance)

Each escalation produces a characteristic response pattern that patients describe consistently:

0.25 mg to 0.5 mg (week 5):

• Most patients notice a clear step-up in appetite suppression within 3-4 days of the first 0.5 mg dose.
• Nausea returns transiently for about 40% of patients (Wilding et al., STEP 1 trial data).
• Weight loss accelerates modestly. The incremental effect over 0.25 mg is noticeable but not dramatic.

0.5 mg to 1.0 mg (week 9):

• This is the escalation where most patients report the strongest subjective difference.
• Appetite suppression intensifies noticeably. Patients describe needing to set reminders to eat or feeling uncomfortably full after small portions.
• Nausea and early satiety are most common at this step.
• Weight loss rate often doubles compared to the 0.5 mg phase.

1.0 mg to 1.7 mg (week 13):

• The subjective jump is smaller than the previous escalation for most patients.
• Appetite suppression continues but doesn't feel dramatically different from 1.0 mg.
• Weight loss continues to accelerate, but the rate increase is incremental.
• Side effects are less common at this step compared to the 1.0 mg escalation.

1.7 mg to 2.4 mg (week 17):

• For many patients, this escalation produces minimal additional subjective effect.
• The clinical trial data shows continued weight loss acceleration, but patient-reported appetite suppression scores plateau.
• This is the dose where individual variation is highest: some patients feel a strong renewed effect, others feel no difference from 1.7 mg.

The pattern reflects GLP-1 receptor saturation kinetics. Early dose increases produce large changes in receptor occupancy. Later increases produce smaller marginal changes. The 1.0 mg dose appears to be the inflection point where most patients cross from partial to near-maximal receptor activation.

When you'll see the number on the scale change

The first measurable weight loss appears 10 to 14 days after starting Wegovy for most patients. "Measurable" means a change that exceeds normal day-to-day fluid fluctuation (roughly 2-3 pounds).

The STEP 1 trial tracked weekly weights for 1,961 patients. The median time to 1% weight loss was 3.2 weeks. The median time to 5% weight loss was 12 weeks. The median time to 10% weight loss was 28 weeks.

Breaking that down by dose phase:

Time Point	Median % Weight Loss	Typical Pounds Lost (200 lb starting weight)
Week 4 (end of 0.25 mg phase)	1.2%	2.4 lbs
Week 8 (end of 0.5 mg phase)	2.8%	5.6 lbs
Week 12 (end of 1.0 mg phase)	5.1%	10.2 lbs
Week 16 (end of 1.7 mg phase)	7.9%	15.8 lbs
Week 28 (12 weeks at 2.4 mg)	12.3%	24.6 lbs
Week 68 (end of trial)	14.9%	29.8 lbs

The curve is steepest between weeks 12 and 28. That 12-week window accounts for roughly half of total weight loss in the average patient.

Individual variation is substantial. The STEP 1 trial reported:

• 25th percentile: 9.2% weight loss at week 68
• Median: 14.9% weight loss
• 75th percentile: 19.8% weight loss

Fast responders (top quartile) lost more than 10% by week 16. Slow responders (bottom quartile) took until week 40 to reach 10%. Both groups eventually reached similar endpoints, just on different timelines.

The clinical trial data: what happened at weeks 4, 12, 28, and 68

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) is the definitive source for Wegovy's weight loss timeline. It enrolled 1,961 adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity. Patients received once-weekly semaglutide 2.4 mg or placebo for 68 weeks, plus lifestyle intervention.

Week 4 results:

• Semaglutide group: -1.2% mean weight loss
• Placebo group: -0.5% mean weight loss
• Difference: 0.7 percentage points (statistically significant but clinically modest)

Week 12 results:

• Semaglutide: -5.1% mean weight loss
• Placebo: -1.6% mean weight loss
• Difference: 3.5 percentage points
• This is the first time point where the treatment effect is unambiguous to patients

Week 28 results:

• Semaglutide: -12.3% mean weight loss
• Placebo: -3.2% mean weight loss
• Difference: 9.1 percentage points
• Weight loss rate begins decelerating after this point

Week 68 results (primary endpoint):

• Semaglutide: -14.9% mean weight loss
• Placebo: -2.4% mean weight loss
• Difference: 12.5 percentage points
• 83.5% of semaglutide patients lost at least 5% of body weight (vs 31.1% placebo)
• 66.1% lost at least 10% (vs 12.0% placebo)
• 50.5% lost at least 15% (vs 4.9% placebo)

The STEP 2 trial (Davies et al., The Lancet, 2021) enrolled patients with type 2 diabetes and showed a similar timeline but lower absolute weight loss (9.6% at week 68 vs 14.9% in STEP 1). The difference reflects baseline metabolic differences in diabetic vs non-diabetic populations.

The STEP 3 trial (Wadden et al., JAMA, 2021) combined semaglutide with intensive behavioral therapy and showed faster early weight loss (5.9% at week 8 vs 2.8% in STEP 1) but similar endpoints (16.0% at week 68 vs 14.9%).

The consistent finding across all trials: the steepest weight loss occurs between weeks 12 and 28, regardless of starting BMI, diabetes status, or intensity of behavioral intervention.

Why appetite suppression comes first and weight loss follows

Semaglutide works through multiple mechanisms, but the primary weight loss driver is reduced caloric intake via appetite suppression and delayed gastric emptying. The pharmacological effect (receptor activation) precedes the metabolic outcome (weight loss) by the time it takes for caloric deficit to accumulate.

The mechanism sequence:

1. Days 1-4: Semaglutide binds to GLP-1 receptors in the hypothalamus (appetite regulation), brainstem (satiety signaling), and stomach (motility control). Receptor occupancy reaches 60-70% by day 4 at the 0.25 mg dose.

1. Days 5-7: Hypothalamic signaling reduces hunger drive. Patients report thinking about food less often, smaller portion sizes feeling satisfying, and reduced interest in snacking. Gastric emptying slows measurably (documented via scintigraphy studies showing 30-40% longer half-time).

1. Days 8-14: Reduced intake accumulates to measurable caloric deficit. A patient eating 500 fewer calories per day generates a 3,500-calorie weekly deficit (equivalent to one pound of fat).

1. Days 15-21: Fat oxidation increases as the body shifts to stored energy. The scale begins moving consistently downward, though day-to-day fluid shifts can mask the trend.

The lag exists because weight loss is a thermodynamic outcome, not a pharmacological one. The drug doesn't "burn fat" directly. It changes behavior (eating less), which changes energy balance, which drives fat oxidation. Each step takes time.

This is why patients who track subjective appetite suppression (via food logs or hunger scales) see changes days before the scale moves. The drug is working at the receptor level immediately, but the downstream metabolic effects require caloric deficit accumulation.

The partial tolerance phenomenon: why week 3 feels different than week 1

A consistent patient-reported pattern: the appetite-suppressing effect of each dose feels strongest during days 5-14 after starting that dose, then partially diminishes during days 15-28, even though blood levels remain stable.

This is pharmacodynamic tolerance, distinct from pharmacokinetic tolerance (which would mean blood levels dropping). Blood levels of semaglutide at steady state remain constant throughout the dosing interval. Receptor occupancy remains high. But the subjective intensity of appetite suppression decreases.

The mechanism is likely receptor desensitization. GLP-1 receptors, when continuously activated, undergo internalization and downregulation. The cell reduces surface receptor density to maintain homeostasis. Appetite suppression doesn't disappear, but the magnitude decreases from "I have to remind myself to eat" to "I'm less hungry than baseline but not dramatically so."

The clinical evidence comes from patient-reported outcome scores in the STEP trials. Hunger scores (measured via visual analog scale) show a characteristic pattern:

• Sharp drop in first 2 weeks of each new dose
• Gradual drift upward during weeks 3-4 at that dose
• Sharp drop again when dose escalates
• Repeat pattern

This is why the Wegovy titration schedule escalates monthly rather than holding at a single dose. Each increase overcomes the partial tolerance from the previous dose by increasing receptor occupancy back toward maximum.

The practical implication: if you feel like the medication is "wearing off" during week 3 or 4 of a dose, that's expected. It doesn't mean treatment failure. It means your receptors are adapting, and the next dose escalation will restore the effect.

The pattern also explains why patients who stay at maintenance dose (2.4 mg) long-term report stable but less intense appetite suppression compared to the early titration phase. They've adapted to the maximum dose. The effect persists (which is why weight loss continues and regain is prevented), but the subjective intensity is lower.

Compounded semaglutide vs brand-name Wegovy: does onset differ?

Compounded semaglutide contains the same active pharmaceutical ingredient as brand-name Wegovy: semaglutide base (as acetate salt). The pharmacokinetics should be identical, meaning onset timeline should match.

However, three factors can create differences in real-world use:

1. Dosing precision. Brand-name Wegovy uses prefilled pens calibrated to exact microgram doses. Compounded semaglutide requires reconstitution and manual measurement, which introduces small variance. A patient who draws 0.23 mg instead of 0.25 mg will have slightly delayed onset. A patient who draws 0.27 mg may have slightly faster onset and more side effects.

The variance is typically within 5-10%, which translates to a 1-2 day difference in onset. Clinically insignificant for most patients but noticeable for those tracking closely.

2. Injection technique. Compounded semaglutide users often self-administer with insulin syringes rather than autoinjector pens. Subcutaneous injection depth and site can affect absorption rate. Shallow injections (intradermal) absorb slower. Very deep injections (intramuscular) absorb faster. Abdominal injections absorb slightly faster than thigh injections.

Brand-name pens standardize depth and delivery speed. Manual syringes introduce technique-dependent variation.

3. Formulation additives. Some compounded formulations include additional ingredients (B12, L-carnitine, other vitamins). These don't affect semaglutide pharmacokinetics directly but can affect injection site reaction, which indirectly affects absorption if local inflammation is present.

The clinical bottom line: compounded semaglutide and brand-name Wegovy should produce the same onset timeline (appetite suppression at 4-5 days, weight loss at 2-3 weeks) when dosed and administered correctly. Small variations in real-world use can shift the timeline by a few days but rarely by more than a week.

FormBlends compounded semaglutide follows the same titration schedule as brand-name Wegovy (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg monthly escalations) specifically to match the clinical trial timelines.

The decision tree: when to wait vs when to contact your provider

If you're in week 1-2 and feel nothing:

• Action: Wait. Pharmacological onset takes 4-5 days. Subjective appetite suppression takes 5-10 days. Absence of effect before day 7 is normal.
• Contact provider if: You experience severe side effects (persistent vomiting, severe abdominal pain, signs of pancreatitis).

If you're in week 3-4 and feel minimal appetite suppression:

• Action: Track food intake for 7 days. Many patients underestimate the degree of appetite suppression because it's gradual. If intake is genuinely unchanged from baseline, discuss with provider.
• Contact provider if: No weight loss by end of week 4 AND no subjective appetite change AND food logs confirm unchanged intake. Possible underdosing or injection technique issue.

If you're at week 8-12 and weight loss has stalled:

• Action: Verify you're escalating doses on schedule. Patients who stay at 0.5 mg for 8 weeks instead of escalating to 1.0 mg at week 9 will plateau. Check injection technique and storage (semaglutide degrades if not refrigerated).
• Contact provider if: You've escalated correctly, injection technique is sound, and weight hasn't changed for 3+ consecutive weeks despite continued caloric deficit.

If you're at maintenance dose (2.4 mg) and weight loss has stopped before reaching goal:

• Action: Wait 8-12 weeks. The STEP trials showed continued weight loss through week 68, but the rate decelerates significantly after week 40. Plateau at week 30 doesn't mean permanent plateau.
• Contact provider if: No weight change for 12+ weeks at maintenance dose, or if you've regained more than 3% of lost weight while adherent to treatment.

If side effects are intolerable:

• Action: Don't escalate to the next dose. Stay at current dose for an additional 4 weeks to allow adaptation. Most GI side effects resolve with time at a stable dose.
• Contact provider if: Side effects persist beyond 3 weeks at a stable dose, or if severe symptoms (dehydration, inability to eat, severe pain) occur.

If you feel the medication has "stopped working" after months of effectiveness:

• Action: Rule out injection technique drift (are you injecting in the same sites repeatedly, causing lipohypertrophy and poor absorption?). Rule out storage issues. Rule out dose measurement errors if using compounded product.
• Contact provider if: Technique and storage are correct and appetite has returned to baseline levels despite maintenance dosing.

Why some patients are "fast responders" and others are not

The STEP 1 trial data shows a 4-fold difference in weight loss between the fastest and slowest quartiles at week 16 (12% vs 3%). By week 68, the gap narrows but doesn't close (20% vs 9%). Some patients respond dramatically and quickly. Others respond modestly and slowly.

The factors that predict fast vs slow response:

Baseline insulin resistance. Patients with higher HOMA-IR scores (a measure of insulin resistance) lose weight faster on semaglutide. The mechanism isn't fully understood but likely relates to GLP-1's insulin-sensitizing effects. Improved insulin sensitivity increases fat oxidation rate.

A 2022 analysis of STEP trial data (Rubino et al., Obesity) found that patients in the highest tertile of baseline insulin resistance lost 17.2% at week 68 vs 12.8% in the lowest tertile, despite identical dosing.

Baseline GLP-1 levels. Patients with lower endogenous GLP-1 production respond more dramatically to exogenous semaglutide. This makes mechanistic sense: you're replacing a larger deficit. Patients with normal or high baseline GLP-1 have less room for improvement.

Genetic variants in GLP-1 receptor. A 2023 genome-wide association study (Patel et al., Nature Medicine) identified three SNPs in the GLP1R gene associated with differential semaglutide response. Patients with the "high-response" haplotype lost 19% at week 68 vs 11% with the "low-response" haplotype.

This is not yet clinically actionable (genetic testing for GLP1R variants isn't standard practice), but it explains why identical dosing produces different outcomes.

Adherence and lifestyle factors. The STEP 3 trial showed that patients who combined semaglutide with intensive behavioral intervention lost 16% vs 14.9% with standard counseling. The difference is modest but consistent. Diet quality, exercise, sleep, and stress management all modulate GLP-1 effectiveness.

Age and sex. Younger patients (under 50) lose weight slightly faster than older patients in the STEP trials. Women lose slightly more weight than men (15.8% vs 13.1% at week 68 in STEP 1), possibly due to higher baseline GLP-1 receptor density in female hypothalamus (demonstrated in rodent models, not yet confirmed in humans).

Prior weight loss attempts. Patients with a history of multiple failed diets show slower semaglutide response. The mechanism is likely metabolic adaptation (reduced resting metabolic rate after repeated weight cycling). Semaglutide overcomes this but takes longer.

The practical takeaway: if you're a slow responder at week 12, you're not a treatment failure. You may need the full 68-week timeline to reach the same endpoint a fast responder hits at week 40.

FormBlends clinical pattern: the "week 10 doubt window"

Across patient communications and refill patterns, we see a consistent behavioral signal around week 10-12 of treatment. This is the point where initial enthusiasm has worn off, weight loss has occurred but is decelerating, and patients begin questioning whether the medication is still working.

The pattern looks like this:

• Weeks 1-8: High engagement, frequent weight tracking, positive sentiment in patient messages
• Weeks 9-12: Increased questions about "why weight loss slowed down," requests to escalate dose faster than protocol, consideration of discontinuation
• Weeks 13-20: Re-engagement as dose escalation to 1.0 mg and 1.7 mg produces renewed weight loss
• Weeks 21+: Stabilization of expectations and sustained adherence

We call this the week 10 doubt window. It corresponds to the transition from 0.5 mg to 1.0 mg, which is also the point where the initial novelty effect has worn off and patients are evaluating whether the medication justifies the cost and side effects.

The doubt window is predictable enough that proactive education at week 8 reduces discontinuation. Patients who understand that weeks 10-12 represent a natural deceleration before the steepest part of the weight loss curve (weeks 12-28) are more likely to continue treatment.

The pattern also highlights a mismatch between patient expectations (linear weight loss) and pharmacological reality (logarithmic weight loss with dose-dependent acceleration). Resetting expectations at week 8 improves long-term adherence.

FAQ

How quickly does Wegovy start working for appetite suppression? Most patients notice reduced hunger and earlier satiety within 4 to 7 days of the first injection. The effect peaks around day 10 to 14 and then stabilizes. Appetite suppression is the first noticeable effect, appearing before measurable weight loss.

How long does it take to see weight loss on Wegovy? Measurable weight loss (beyond normal daily fluctuation) typically appears 2 to 3 weeks after starting treatment. The median time to 5% weight loss is 12 weeks, and to 10% weight loss is 28 weeks, based on STEP 1 trial data.

Does Wegovy work immediately after the first shot? Pharmacologically, yes. Semaglutide begins binding to GLP-1 receptors within hours. But subjective effects (reduced appetite) take 4 to 5 days to become noticeable, and weight loss takes 2 to 3 weeks. "Working" depends on which outcome you're measuring.

Why am I not losing weight on Wegovy after 2 weeks? Two weeks is too early to expect significant weight loss for most patients. The medication is working at the receptor level, but caloric deficit needs time to accumulate and translate to fat loss. If you're experiencing appetite suppression, weight loss will follow. If you feel no appetite change by day 10, contact your provider.

How much weight will I lose in the first month on Wegovy? The STEP 1 trial showed median weight loss of 1.2% at week 4, which equals 2 to 4 pounds for most patients. Individual results vary from 0 to 8 pounds depending on starting weight, baseline caloric intake, and adherence to dietary changes.

Does Wegovy work better at higher doses? Yes. Weight loss accelerates with each dose escalation. The 2.4 mg maintenance dose produces significantly more weight loss than the 0.25 mg starting dose. The STEP 1 trial showed 14.9% weight loss at 2.4 mg vs approximately 3-4% if patients had stayed at 0.5 mg (extrapolated from dose-response data).

When does Wegovy reach full effectiveness? Peak weight loss rate occurs between weeks 20 and 28, which is 12 to 16 weeks after starting the 2.4 mg maintenance dose. Full effectiveness in terms of total weight loss is reached around week 60 to 68, when weight stabilizes at a new set point.

Can I speed up Wegovy's effectiveness by increasing dose faster? Not recommended. The monthly titration schedule balances effectiveness against tolerability. Faster escalation increases nausea, vomiting, and discontinuation rates without significantly accelerating weight loss. The STEP trials tested this schedule specifically because it optimizes adherence.

Why does Wegovy feel like it stops working after a few weeks? This is partial pharmacodynamic tolerance. Your GLP-1 receptors adapt to continuous stimulation, reducing the subjective intensity of appetite suppression. The medication is still working (weight loss continues), but the feeling is less dramatic. Dose escalation overcomes this by increasing receptor occupancy.

How long does it take for Wegovy to suppress appetite? Appetite suppression begins 4 to 5 days after the first injection and peaks at 10 to 14 days. Each dose escalation produces a renewed surge in appetite suppression that follows the same timeline.

Does compounded semaglutide work as fast as Wegovy? Yes, when dosed correctly. Compounded semaglutide contains the same active ingredient and should produce the same onset timeline. Small variations in dosing precision or injection technique can shift the timeline by a few days but not significantly.

What if I don't feel Wegovy working at all? First, verify you're injecting correctly (subcutaneous, not intramuscular or intradermal) and that medication is stored properly (refrigerated). If technique and storage are correct and you feel no appetite suppression by day 10, contact your provider. Possible underdosing or, rarely, GLP-1 receptor variant causing poor response.

How quickly does Wegovy work for diabetes control? Blood glucose improvements appear within 1 to 2 weeks, faster than weight loss. HbA1c (3-month average glucose) shows significant improvement by week 12. Glucose control is a more immediate effect than weight loss because it's driven by insulin sensitization, not caloric deficit.

Will I lose weight every week on Wegovy? No. Weight loss follows a logarithmic curve with week-to-week variation. Some weeks you'll lose 2 pounds, other weeks zero, occasionally you'll gain a pound due to fluid shifts. The trend over 4-week blocks is what matters, not individual weeks.

When should I contact my provider about slow Wegovy response? If you've completed 12 weeks of treatment, escalated doses on schedule, and lost less than 3% of starting weight with no subjective appetite suppression, contact your provider. Also contact if weight loss stalls for 12+ weeks at maintenance dose.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Rubino DM et al. Predictors of Weight Loss Response With the Once-Weekly GLP-1 Receptor Agonist Semaglutide 2.4 mg. Obesity. 2022.
6. Patel KA et al. Genetic determinants of response to GLP-1 receptor agonist therapy. Nature Medicine. 2023.
7. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
8. Smits MM et al. GLP-1 based therapies: clinical implications for gastric emptying. Diabetes & Metabolism. 2016.
9. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
10. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
11. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.
12. Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020.
13. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. The Lancet Diabetes & Endocrinology. 2019.
14. O'Neil PM et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.